Two-Pronged Drug Combination for Advanced Prostate Cancer: Fadraciclib Plus Ipatasertib (or Capivasertib)

Scientists at The Institute of Cancer Research in London have identified a combination therapy that may benefit up to 40 percent of men with advanced prostate cancer, particularly those whose tumors have become resistant to hormone therapies. This approach targets two proteins essential for cancer cell survival: MCL1 and AKT. Direct inhibition of MCL1 has […]

Self-Assembled Nano-PROTAC to Improve Targeted Therapy in Castration-Resistant Prostate Cancer

A new study published in Nature Signal Transduction and Targeted Therapy reports a major leap in the design of targeted cancer therapies through the development of an in vivo self-assembled nano-PROTAC (proteolysis targeting chimera) system capable of delivering dual-targeted degradation in castration-resistant prostate cancer (CRPC).​ PROTACs have reshaped the drug discovery landscape by inducing selective […]

Dual Enzyme Blockade Weakens Prostate Cancer Tumors and Enhances Treatment Effectiveness

Researchers have identified two enzymes that serve as critical guardians of prostate cancer cell survival, opening new avenues for enhancing treatment outcomes in one of the most common cancers affecting men worldwide. The study, published in the Proceedings of the National Academy of Sciences, demonstrates that blocking these molecular chaperones can destabilize cancer cells and […]

Scientists Develop “Velcro” Cancer Treatment That Works Across Many Tumor Types

Researchers at the University of California, Irvine have developed an innovative cancer immunotherapy called GlyTR, a new class of treatment that uses a “velcro-like” mechanism to target sugar molecules abundantly present on cancer cells. Their findings were published in September 2025 in the prestigious journal Cell, marking a significant advancement in cancer immunotherapy. Traditional immunotherapies […]

New Study Uncovers Mechanism Behind T-Cell Exhaustion, Offering Hope for Prostate Cancer Immunotherapy

A study from The Ohio State University Comprehensive Cancer Center has illuminated a critical reason why cancer immunotherapy often fails: T-cell exhaustion driven by a novel stress pathway called TexPSR (proteotoxic stress response in T-cell exhaustion). Published in the prestigious journal Nature, this discovery reveals a proteotoxic shock in exhausted T cells caused by the […]